Craft
Ablynx

Ablynx

Revenue

€85.2 M

FY, 2016

Ablynx Summary

Company summary

Overview
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It offers a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.
Type
Subsidiary
Founded
2001
HQ
Gent, BE | view all locations
Website
http://www.ablynx.com/
Cybersecurity rating
Sectors

Key people

  • Bernard Delaey

    Bernard Delaey, Senior Director, Regulatory Affairs

  • Carmen Fleurinck

    Carmen Fleurinck, Senior Medical Director

  • Malgorzata Ciesiolka

    Malgorzata Ciesiolka, Director, Business Development

  • Anne Brochot, Director, Pharmacometrics

Operating MetricsView all

Clinical Programs

45

Q2, 2017

Patents (Foreign)

180

Q2, 2017

Patents (US)

50

Q2, 2017

LocationsView all

1 location detected

  • Gent, Vlaanderen HQ

    Belgium

    Technologiepark-Zwijnaarde 21

Footer menu